샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757796

다가백신 시장

Multivalent Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 278 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

다가백신 세계 시장은 2030년까지 157억 달러에 도달

2024년에 94억 달러로 추정되는 다가백신 세계 시장은 2024-2030년 분석 기간에 CAGR 9.0%로 성장하여 2030년에는 157억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 결합 백신은 CAGR 10.8%를 나타내고, 분석 기간 종료시에는 99억 달러에 이를 것으로 예측됩니다. 불활성화/아단위 백신 분야의 성장률은 분석 기간중 CAGR 6.0%로 추정됩니다.

미국 시장은 26억 달러, 중국은 CAGR14.4%로 성장 예측

미국의 다가백신 시장은 2024년에 26억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 35억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 14.4%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 4.4%와 8.7%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 6.1%를 보일 전망입니다.

세계의 다가백신 시장 - 주요 동향과 촉진요인 정리

다가백신이 예방접종 프로그램의 전략적 우선순위인 이유는 무엇인가?

하나의 제형으로 여러 병원체 균주 및 병원체 종을 예방하는 다가백신은 전 세계 예방접종 전략에 있어 점점 더 중요해지고 있습니다. 단일 항원을 표적으로 하는 단일가 백신과 달리 다가 백신은 광범위한 방어력을 제공하므로 주사 횟수를 줄이고, 예방접종 일정을 간소화하며, 환자의 순응도를 향상시킬 수 있습니다. 이러한 백신은 소아과, 여행, 집단 발병 등 여러 질병에 대한 동시 예방이 개인과 지역사회 모두에게 중요한 상황에서 특히 유용합니다.

다가백신의 실용적인 장점은 편리함에 그치지 않습니다. 특히 자원이 부족한 환경에서 백신의 보관, 운송 및 투여에 드는 물류 비용을 절감할 수 있습니다. 공중 보건 당국은 대규모 예방접종 캠페인에 다가 백신을 사용함으로써 접점을 최소화하고 의료 자원의 배분을 최적화할 수 있습니다. 전 세계적으로 새로운 바이러스 변종과 공감염의 위협이 대두되는 가운데, 한 번의 접종으로 여러 병원체를 예방할 수 있는 능력은 백신 개발 및 배포의 핵심 목표가 되고 있습니다.

다가백신의 효능과 구성을 향상시키는 기술 발전은 어떤 기술 발전이 이루어지고 있는가?

분자생물학, 보조제 기술, 단백질 공학의 발달로 보다 안정적이고 면역원성이 높으며 광범위하게 예방 효과가 있는 다가 백신의 개발이 가능해지고 있습니다. 재조합 DNA 플랫폼은 단일 벡터나 캐리어에서 여러 항원을 발현할 수 있게 하여 제조 효율과 항원 적합성을 향상시키고 있습니다. 사포닌, toll-like receptor agonist, 지질 기반 나노입자와 같은 새로운 보조제는 반응성을 낮추면서 면역반응을 강화하기 위해 통합되어 있습니다.

또한, 코로나19 백신 경쟁에서 입증된 바와 같이, 바이러스 벡터와 mRNA 플랫폼은 단일 구조로 여러 항원을 코딩할 수 있는 잠재력을 가지고 있기 때문에 DTP(디프테리아, 파상풍, 백일해), MMR(홍역, 볼거리, 풍진), 6가 영아 백신 등 혼합 백신 및 6가 영유아 백신과 같은 새로운 제형은 예방 효과 확대, 내약성 개선, 혼합 접종 스케줄 지원 등을 위해 지속적으로 개선되고 있습니다. 콜드체인 최적화와 내열성 백신 제제는 원격지에서의 다가 백신의 사용 가능성을 높이고 있습니다.

다가백신 수요를 주도하는 질병과 인구 집단은?

소아 예방접종은 다가 백신의 가장 크고 체계적인 이용 사례로, 영유아는 한 번의 주사로 최대 6가지 질병을 예방할 수 있습니다. 장티푸스, A형 간염, B형 간염, 수막염균 감염과 같은 질병에 대한 여행용 백신도 전 세계 여행자들을 위해 자주 병용되고 있습니다. 계절성 및 유행성 독감 백신은 매년 유행하는 독감 바이러스에 맞게 설계되어 위험에 처한 집단에 광범위한 보호를 제공하는 계절 및 유행성 독감 백신 프로그램입니다.

고령자, 면역 결핍자, 의료 종사자는 특히 독감 백신과 코로나19 부스터의 병용 후보물질이 개발 단계에 접어들면서 차세대 다가백신에 있어 중요한 부문이 되고 있습니다. 수의학에서 다가백신은 가축과 반려동물을 여러 바이러스 및 세균 감염으로부터 보호하기 위해 널리 사용되고 있으며, 항균제 사용량을 줄이고 동물의 건강 상태를 개선하는 데 도움이 되고 있습니다. 호흡기세포융합바이러스(RSV), 코로나19, 인플루엔자 항원 조합에 대한 새로운 관심은 성인을 대상으로 한 다가 제품의 기술 혁신을 촉진하고 있습니다.

다가 백신 시장의 성장은 몇 가지 요인에 의해 주도됩니다.

다가 백신 시장의 성장은 효율적인 예방접종 일정에 대한 수요 증가, 동시 감염 발생률 증가, 자원이 부족한 지역에서의 백신 접근성 향상 필요성 등 여러 요인에 의해 주도되고 있습니다. 재조합 기술, 보조제 개발, 벡터 기반 플랫폼의 개발로 인해 보다 복잡하고 안정적인 다가 제제의 설계가 가능해졌습니다. 국제 보건기구의 지원 정책, 소아 및 성인 백신 프로그램에 대한 투자 확대, 팬데믹 시나리오에서 물류 간소화의 필요성 등이 시장 도입을 가속화하고 있습니다. 의료 시스템이 인구 커버리지를 높이고 진화하는 병원체에 대응하기 위해 노력하는 가운데, 다가백신은 세계 예방접종 전략의 최전선에 계속 자리할 것으로 보입니다.

부문

유형별(결합 백신, 불활화 백신 및 아단위 백신, 활성화 백신);용도별(소아, 성인)

조사 대상 기업 예(총 44개사)

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech SE
  • Boehringer Ingelheim GmbH
  • CSL Seqirus
  • CureVac N.V.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • GlaxoSmithKline plc(GSK)
  • Indian Immunologicals Ltd.
  • LimmaTech Biologics AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • VBI Vaccines Inc.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.15

Global Multivalent Vaccines Market to Reach US$15.7 Billion by 2030

The global market for Multivalent Vaccines estimated at US$9.4 Billion in the year 2024, is expected to reach US$15.7 Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$9.9 Billion by the end of the analysis period. Growth in the Inactivated & Subunit Vaccine segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 14.4% CAGR

The Multivalent Vaccines market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 14.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Multivalent Vaccines Market - Key Trends & Drivers Summarized

Why Are Multivalent Vaccines a Strategic Priority in Immunization Programs?

Multivalent vaccines, which protect against multiple strains or species of pathogens in a single formulation, have become increasingly vital to global immunization strategies. Unlike monovalent vaccines that target a single antigen, multivalent formulations offer broad-spectrum protection, thereby reducing the number of injections, simplifying immunization schedules, and improving patient compliance. These vaccines are especially valuable in pediatric, travel, and outbreak-prone contexts where simultaneous protection against several diseases is critical for both individuals and communities.

The practical benefits of multivalent vaccines extend beyond convenience. They reduce logistical costs in vaccine storage, transport, and administration-especially in resource-constrained settings. Public health authorities prefer multivalent solutions for mass immunization campaigns, as they minimize contact points and optimize healthcare resource allocation. As new viral variants and co-infection threats emerge globally, the ability to confer multi-pathogen protection through a single dose is becoming a central objective in vaccine development and deployment.

What Technological Advancements Are Improving the Efficacy and Composition of Multivalent Vaccines?

Advances in molecular biology, adjuvant technology, and protein engineering are enabling the development of more stable, immunogenic, and broadly protective multivalent vaccines. Recombinant DNA platforms allow for the expression of multiple antigens in a single vector or carrier, improving manufacturing efficiency and antigen compatibility. Novel adjuvants such as saponins, toll-like receptor agonists, and lipid-based nanoparticles are being incorporated to enhance immune response while reducing reactogenicity.

Additionally, viral vector and mRNA platforms are being explored for their potential to encode multiple antigens in a single construct, as demonstrated during the COVID-19 vaccine race. Combination vaccines such as DTP (diphtheria-tetanus-pertussis), MMR (measles-mumps-rubella), and newer formulations like hexavalent infant vaccines are being continually refined to extend protection, improve tolerability, and support mixed immunization schedules. Cold chain optimization and thermostable vaccine formulations are also advancing multivalent vaccine usability in remote areas.

Which Diseases and Population Segments Are Driving Demand for Multivalent Vaccines?

Pediatric immunization remains the largest and most structured use case for multivalent vaccines, with infants receiving protection against up to six diseases in a single injection. Travel vaccines for diseases like typhoid, hepatitis A and B, and meningococcal infections are also frequently combined for global travelers. In seasonal and pandemic preparedness programs, multivalent influenza vaccines are designed annually to match circulating strains, providing broad protection in at-risk populations.

Elderly populations, immunocompromised individuals, and healthcare workers are key segments for new generation multivalent vaccines, especially as combination flu and COVID-19 booster candidates enter development. In veterinary medicine, multivalent vaccines are used extensively to protect livestock and pets against multiple viral and bacterial infections, helping reduce antimicrobial use and improve animal health outcomes. Emerging interest in combining respiratory syncytial virus (RSV), COVID-19, and influenza antigens is driving innovation in adult-targeted multivalent products.

The Growth in the Multivalent Vaccines Market Is Driven by Several Factors…

The growth in the multivalent vaccines market is driven by several factors including increasing demand for efficient immunization schedules, rising incidence of co-infections, and the need to enhance vaccine accessibility in resource-limited regions. Advancements in recombinant technology, adjuvant development, and vector-based platforms are enabling the design of more complex yet stable multivalent formulations. Supportive policies by global health organizations, growing investments in pediatric and adult vaccine programs, and the need to simplify logistics in pandemic scenarios are accelerating market adoption. As health systems aim to improve population coverage and respond to evolving pathogens, multivalent vaccines will remain at the forefront of global immunization strategies.

SCOPE OF STUDY:

The report analyzes the Multivalent Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Conjugate Vaccine, Inactivated & Subunit Vaccine, Live Attenuated Vaccine); Application (Pediatrics, Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech SE
  • Boehringer Ingelheim GmbH
  • CSL Seqirus
  • CureVac N.V.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • GlaxoSmithKline plc (GSK)
  • Indian Immunologicals Ltd.
  • LimmaTech Biologics AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • VBI Vaccines Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Multivalent Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Broad-Spectrum Protection Against Infectious Diseases Fuels Development of Multivalent Vaccines
    • OEM Focus on Reducing Doses Per Immunization Cycle Supports Growth in Combined Antigen Formulations
    • Expansion of Pediatric and Routine Immunization Programs Strengthens Use of Multivalent Vaccine Platforms
    • Push for Universal Influenza and Coronavirus Vaccines Accelerates Multivalent Antigen Research
    • Increased Prevalence of Co-Infections Drives Innovation in Multi-Target Vaccine Technologies
    • OEM Development of mRNA-Based Multivalent Vaccines Enhances Speed and Flexibility in Pandemic Response
    • Regulatory Support for Single-Injection Immunization Models Promotes Approval of Combined Vaccine Candidates
    • Growth in Travel and Global Mobility Fuels Demand for Multivalent Protection in Endemic Regions
    • Rising Focus on Elderly and Immunocompromised Populations Strengthens Market for Broad-Protection Vaccines
    • Expansion of Veterinary Multivalent Vaccines Supports Disease Control in Animal Health and Zoonotic Risk
    • Integration of Nanoparticle Carriers and Lipid Formulations Improves Stability and Delivery of Multivalent Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multivalent Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Multivalent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Conjugate Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated & Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Inactivated & Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Inactivated & Subunit Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Live Attenuated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • JAPAN
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • CHINA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • EUROPE
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Multivalent Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • FRANCE
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • GERMANY
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Multivalent Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • INDIA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Multivalent Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Multivalent Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Multivalent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • AFRICA
    • Multivalent Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Multivalent Vaccines by Type - Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Multivalent Vaccines by Type - Percentage Breakdown of Value Sales for Conjugate Vaccine, Inactivated & Subunit Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Multivalent Vaccines by Application - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Multivalent Vaccines by Application - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Multivalent Vaccines by Application - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제